The study treated patients with metastatic prostate cancer with six cycles of docetaxel every 21 days, and the GnRH receptor antagonist degarelix was started either before cycle one, or at cycle five, for seven injections, 28 days apart. The gene discussed is GNRHR; the disease is metastatic prostate carcinoma.